Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Investor Presentation (September 2019)
25 slides from Evofem Biosciences's investor presentation, Sep 4, 2019
Slide 1: Evofem Biosciences Investor Presentation, September 2019
Exhibit 99.1 Evofem Biosciences Investor Presentation, September 2019 Revolutionizing Women’s Sexual and Reproductive Health (Nasdaq: EVFM)
Slide 2: Disclaimer
Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” ”will,” “should,” “expect,” “plan,” “aim,”
Slide 3: Evofem Biosciences at a Glance
Evofem Biosciences at a Glance Core focus: developing Amphora®, our lead Multipurpose Vaginal pH Regulator (MVP-RTM) product candidate, for the prevention of pregnancy and the prevention of chlamydia ©2019 Evofem Biosciences, Inc. | 3
Slide 4: Million U.S. women sexually active and not preventing pregnancy
16 million U.S. women are sexually active and don’t want to become pregnant, however are doing nothing to prevent pregnancy. Source: Derived from NCHS Data Brief No. 173_December 2014 and the 2018 Guttmacher Contraceptive Use in the US Report – July 2018. ©2019 Evofem Biosciences, Inc. | 4
Slide 5: Million women using condoms, withdrawal, or natural family planning
9 million women may have transitioned away from hormones and are using condoms, withdrawal, or natural family planning as their primary method for pregnancy prevention. Source: Derived from NCHS Data Brief No. 173_December 2014 and the 2018 Guttmacher Contraceptive Use in the U.S. Report – July 2018
Slide 6: Chlamydia is the most frequently reported STI in the U.S.
Chlamydia is the most frequently reported STI in the U.S., with 1.7 million new cases reported in 2017. Source: CDC preliminary data in five-year trends in sexually transmitted diseases 2017. ©2019 Evofem Biosciences, Inc. | 6
Slide 7: It's time for another choice – Amphora
Many women take hormonal contraception every day, every week, and every month…yet on average, they only have sex eight times a month. It’s time for another choice – it’s time for Amphora. ©2019 Evofem Biosciences, Inc. | 7
Slide 8: Evofem Biosciences: Clinical Stage Biopharmaceutical Company
Evofem Biosciences A Clinical Stage Biopharmaceutical Company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health • Non-hormonal, acid-buffering MVP-R vaginal gel with bio-adhesive properties Multipurpose Vaginal pH • Desig
Slide 9: Amphora for Pregnancy Prevention
Amphora for Pregnancy Prevention Completed Phase 3 AMPOWER trial in 2H 2018 • Single-arm, open label trial • ~1,400 women, age 18-35 at 112 U.S. sites • Amphora was used in >34,000 acts of intercourse • Achieved strong results that clearly met the FDA's pre-specified primary endpoint • Favorable saf
Slide 10: Adverse Events (AEs) in AMPOWER
Adverse Events (AEs) in AMPOWER The incidence of AEs was low (1.1%), and none of the SAEs were considered definitely related to treatment with Amphora Amphora (N = 1330) n (%) Subjects With ≥ 1 AE 601 (45.2) Subjects With ≥ 1 SAE 14 (1.1) AEs Leading to Early Discontinuation 25 (1.9) Relationship of
Slide 11: Exploratory Sexual Satisfaction Endpoint Findings
Exploratory Sexual Satisfaction Endpoint Findings An almost three fold increase in sexual satisfaction was reported when using Amphora as compared to the previous form of contraception 16.9% of women reported sexual satisfaction 45.5% of women reported an with their previous method increase in sexua
Slide 12: MVP-R Gel Label Expansion Opportunity: Prevention of Chlamydia
MVP-R Gel Label Expansion Opportunity Amphora for the Prevention of Chlamydia Prevention of Chlamydia 1.7M Annually1 Indication1.7M new cases of chlamydia in 2017 inAddressable U.S.* Population AMPREVENCE Phase 2b Clinical Trial 2019 2020 2021 2022 Double-blinded, placebo-controlled efficacy trial a
Slide 13: Female Contraception Today is at Odds With What Women Want
Female Contraception Today is Fundamentally at Odds With What Women Want ~16 MILLION1 ~9 MILLION1 45% American women are Women using condoms, of pregnancies in the U.S. each year sexually active and withdrawal, or the are unplanned2. don’t want to become rhythm method. pregnant, but are Unintended M
Slide 14: Who Are These Million Women?
Who Are These 25 Million Women? Millennials: A healthier lifestyle that doesn’t include hormones in their food, makeup, or birth control Non-hormonal Transition: Concerned about side-effects, long-term impact on health, and ability to get pregnant in the future due to hormones Spacers: Breast-feedin
Slide 15: Attitudinal Segmentation of Potential Amphora Users
Attitudinal Segmentation of Potential Amphora Users Source: Integrated Insights Amphora Consumer Segmentation Report, March 2016. THIS: “Moving on from hormones to Amphora” * Stronger preference for non-hormonal contraceptives * Less satisfied with current contraception + Use Amphora as primary meth
Slide 16: Amphora Early-Adopter Health Care Providers
Amphora Early-Adopter Health Care Providers (HCPs)* • Wants to empower women with reproductive freedom Segment C: • Dedicated time to contraceptive counseling Crusader Kelly • High concern for patients who do not use contraception Female OB/GYN • Majority of patients are between the ages of 20-39 an
Slide 17: HCPs Anticipate Amphora Will Be 2nd Highest Birth Control Prescribed
1024 HCPs Anticipate Amphora will be the 2nd Highest Form of Birth Control Prescribed to Women* HCP Allocation of Primary Birth Control Method Following Amphora Approval (%) Total (n-1024) % %Δ Oral Contraceptives (Regular, 28-day) 26% -14% Amphora 15% Hormonal IUD 11% -10% Condom 8% -20% Injectable
Slide 18: Positive Experience with Amphora Results in Excitement
Positive Experience with Amphora Results in Excitement and Anticipation for a New Birth Control Option “ I liked how I could use Amphora whenever I needed to and not everyday. I don’t like adding hormones to my body.” I am very satisfied and hope I can find it in the market.” – AMPOWER Women* “ They
Slide 19: Sales and Marketing Strategy Designed to Maximize Amphora Adoption
Sales and Marketing Strategy Designed to Maximize Amphora Adoption Sales Force Structure • ~12 Regional Managers • ~125 Representatives • 100% coverage of top prescribers of contraception Direct-to-Consumer Advertising • 6 months post launch Market Access Coverage • 8 National Account Managers 98% o
Slide 20: Amphora Potential Commercial Value
Amphora Potential Commercial Value Currently: 16 million women are sexually active, but do nothing to prevent pregnancy 9 million women using condoms, withdrawal, or the rhythm method Doing the Math: If just 1 in 25 of these women were to use Amphora at the same time… filling the script 7 times that
Slide 21: Significant Rest of World Commercial Potential
Significant Rest of World Commercial Potential • Women across the globe are seeking to avoid hormones in their birth control • In the EU ~29% have discontinued OCs, with a ‘desire to avoid hormones’ being the most common reason stated1 • ~30% of women in the APAC region display hormone avoidance ten
Slide 22: The MVP-R Franchise
The MVP-R Franchise Her need NOW Birth Control that conforms to her life, not the other way around Multipurpose Vaginal pH Regulator (MVP-R) AMPHORA AMPHORA AMPHORA birth control urogenital chlamydia sexual pleasure and gonorrhea The birth control indication will disrupt the marketplace in all the b
Slide 23: Significant Achievements 2018 and 2019 YTD
Significant Achievements 2018 and 2019 YTD Research and Development ✓ Completed AMPOWER enrollment: Amphora for prevention of pregnancy ✓ Announced top-line data: Amphora for prevention of pregnancy ✓ Positive Type B meeting with FDA: Amphora for prevention of pregnancy ✓ Completed AMPREVENCE enroll
Slide 24: Multiple Near-Term Catalysts
Multiple Near-Term Catalysts Top-line data: Amphora for prevention of chlamydia (Ph2b) Nov. 2019^ Re-submit NDA: Amphora for prevention of pregnancy Q4 2019^ Ex-U.S. Licensing Agreement: Amphora commercialization partner due diligence process and agreement completion Commercial launch: Amphora for p
Slide 25: Investor Relations Contact
Investor Relations Contact Amy Raskopf E: araskopf@evofem.com (Nasdaq: EVFM) C: (917) 673-5775
Evofem Biosciences — Investor Presentation (September 2019) on 6ix